Skip to main content
  • Home
  • Incretin Management in Type 2 Diabetes

Incretin Management in Type 2 Diabetes

Topic:
  • MI/ACS

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Please Note

This content is not indented for UK HCPs

Overview

In this educational hub ‘Incretin Management in Type 2 Diabetes’ the faculty present the importance of screening and early intensification for better glycaemic control and improved vascular and mortality outcomes in type 2 diabetes.

In this series of CME accredited videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.



The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.


This programme is supported by an unrestricted educational grant by Novo Nordisk A/S. The scientific programme has not been influenced in any way by the sponsors.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
 

The session of ‘Incretin Management in Type 2 Diabetes’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Target Audience

This programme is intended to educate:

  • Primary care physicians (PCPs)/ General Practitioners (GPs)
  • Endocrinologists
  • Diabetologists
  • Nurses

Learning Objectives

The overall programme, ‘Incretin Management in Type 2 Diabetes’’, endeavours to best address the following learning objectives:

  • Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
  • Identify underlying facets of clinical inertia in T2DM care
  • Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
  • Recall efficacy & the mode of action of various incretin-based treatments
  • Adopt an early, intensive glucose-lowering strategy in appropriate individuals 
  • Select appropriate incretin treatment & dosing regimens according to patient profiles 
  • Identify individuals likely to gain cardiovascular benefit from GLP-1RAs 
  • Select appropriate actions following adverse events from incretin-based treatments
Register now Log in

Module

Title

Duration

Speakers

Session 1 Diabetes pathophysiology and the 'ominous octet' 10 minutes Silvio Inzucchi
Session 2 The incretin system & incretin-targeting agents 10 minutes Silvio Inzucchi
Session 3 Therapeutic inertia in T2DM 10 minutes Kamlesh Khunti
Session 4 Early glycaemic control in T2DM 10 minutes Kamlesh Khunti
Session 5 The use of GLP-1 RAs in T2DM 10 minutes Sarah Davies
Session 6 Incretin-based drugs: What does the data say? 10 minutes Sarah Davies
Session 7 Incretin-based drugs: Mode of action/delivery & dosing schedule 10 minutes Su Down
Session 8 Appropriate prescribing practices 10 minutes Su Down
Session 9 Beyond glycaemic control: Cardiovascular benefits 10 minutes Mikhail Kosiborod
Session 10 Beyond glycaemic control: Weight control 10 minutes Mikhail Kosiborod
Session 1.

Diabetes pathophysiology and the 'ominous octet'

Duration: 10 minutes

Speakers: Silvio Inzucchi

Session 2.

The incretin system & incretin-targeting agents

Duration: 10 minutes

Speakers: Silvio Inzucchi

Session 3.

Therapeutic inertia in T2DM

Duration: 10 minutes

Speakers: Kamlesh Khunti

Session 4.

Early glycaemic control in T2DM

Duration: 10 minutes

Speakers: Kamlesh Khunti

Session 5.

The use of GLP-1 RAs in T2DM

Duration: 10 minutes

Speakers: Sarah Davies

Session 6.

Incretin-based drugs: What does the data say?

Duration: 10 minutes

Speakers: Sarah Davies

Session 7.

Incretin-based drugs: Mode of action/delivery & dosing schedule

Duration: 10 minutes

Speakers: Su Down

Session 8.

Appropriate prescribing practices

Duration: 10 minutes

Speakers: Su Down

Session 9.

Beyond glycaemic control: Cardiovascular benefits

Duration: 10 minutes

Speakers: Mikhail Kosiborod

Session 10.

Beyond glycaemic control: Weight control

Duration: 10 minutes

Speakers: Mikhail Kosiborod

Course Director

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes. He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research

View full profile

Speaker

Silvio Inzucchi

Yale University, School of Medicine

Dr Inzucchi is a Professor of Medicine at the Yale University School of Medicine in New Haven, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship. 

View full profile

Speaker

Kamlesh Khunti

University of Leicester, Leicester, UK

Prof Khunti is the Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Co-Director of the Leicester Diabetes Centre.  His work has greatly influenced guidelines on the screening and management of people with diabetes.

View full profile

Speaker

Sarah Davies

Woodlands Medical Centre

Dr Davies graduated from the University of Wales College of Medicine in 2003, initially pursuing a career in medicine, especially diabetes and endocrinology. She then made the move to General Practice and continued her interest in diabetes, completing the Cardiff Postgraduate diploma in diabetes.

View full profile

Speaker

Su Down

Somerset NHS Foundation Trust

Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset.  Her Diabetes nursing career started in 1989, when she set up the diabetes specialist nursing service in Yeovil District Hospital.  Su took up the role of Nurse Consulta

View full profile

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity
  • 1.00 European Board for Accreditation in Cardiology (EBAC)

Learning objectives

  • Discuss the current practice gaps in hypercholesterolaemia management
  • Recall best practice for assessing CV risk, defining LDL-C targets and offering patient education
  • Stratify patients by CV risk category
  • Select cholesterol-lowering therapies according to risk category and LDL-C target
See more
P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients
  • 1.00 EBAC

Learning objectives

  • Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
  • Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
  • Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case
See more
TIO 2020 – CHIP Live Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Focus on Calcified Lesions
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Technologies and Controversies
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Trials
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Live TAVI Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – CTO Live Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Focus on CTO
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more